INCITE NEWS

LIFE SCIENCE INVESTORS GET THEIR DUE

Investing in life science products from biotechnology to diagnostic products can mean high risk and long waits for investors wanting ten times their initial investment. Most venture capital investors seek the crystal balls of freshly minted MBAs and discussions with scientists and physicians for insights about new medical technologies. However, the investment wildcards include unanticipated regulatory delays and competitive product offerings from unknown sources that require experienced functional experts to evaluate. Without this experienced input, life science investors prefer a conservative approach to investments and are currently funding companies and products with features similar to existing fare. So, how do innovative products get out of the lab and into the market?

INCITE WORLD has developed an answer that provides life science investors with a more meaningful evaluation of candidate investments. The Company has developed a unique business model by offering a penetrating examination of life science technologies and the level of risk associated with commercializing the innovation. INCITE achieves these objectives using tightly-knit group of domain experts who work together to produce well-orchestrated due diligence reports.

"INCITE WORLD engages senior level consultants with a minimum of ten years of industry experience to accelerate new products into commercialization", says Jayme Norrie, Chief Strategic Officer, "But we quickly realized these same consultants could be deployed to evaluate investment risk by providing experienced analysis of all issues related to commercializing the innovations. We use this team to critique candidate portfolio companies for investors and show them what the actual costs, strengths, and weaknesses are."

INCITE WORLD currently has almost 100 consultants who specialize in various aspects of life science product delivery. These scientists, pharmacists, physicians and biomedical engineers have expertise in regulatory affairs, clinical development, medical device design, pricing, reimbursement, manufacturing, market analysis, and marketing assistance applicable to mid-size life science companies building out their infrastructure. The talents of these experienced consultants can also be applied to assessment of investment risk.

"The synergy among these consultants promises great potential for INCITE and its clients", says Bill Pagels, INCITE's Executive Director, New Innovations, "Mid-sized companies are under the gun to perform with limited resources because they don't have enough funding to hire all of the personnel required for such an arduous task. Establishing a link between life science companies, investors, and our support of industry executives looking for products to bring into large industry pipelines is the focus of our business model. It's a whole ecosystem in one engaged resource."

"We've brought in MBAs as well", adds Norrie, "but ours come from business development positions in life science companies so they have experience in licensing deals, financial forecasting for life science products, and working with the investment community."

INCITE WORLD, based in Utah, is composed of industry professionals drawn from throughout the US and Canada. INCITE's consultants have been hand-picked for their domain expertise in all aspects of life science product development and commercialization applicable also to investor and partnering due

Contact: